Critics of most-favored-nation drug pricing have warned that it could reduce patient access to certain drugs, raise the prices of other drugs, and decrease research and development for new drugs.

The Food and Drug Administration (FDA) is requiring class-wide label changes for opioid medications to provide additional information on the risks associated with long-term use.